These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21547597)

  • 21. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
    Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
    Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial.
    Hernando JJ; Park TW; Kübler K; Offergeld R; Schlebusch H; Bauknecht T
    Cancer Immunol Immunother; 2002 Mar; 51(1):45-52. PubMed ID: 11845259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial.
    Baek S; Kim YM; Kim SB; Kim CS; Kwon SW; Kim Y; Kim H; Lee H
    Cell Mol Immunol; 2015 Jan; 12(1):87-95. PubMed ID: 24976269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.
    Rodríguez-Ruiz ME; Perez-Gracia JL; Rodríguez I; Alfaro C; Oñate C; Pérez G; Gil-Bazo I; Benito A; Inogés S; López-Diaz de Cerio A; Ponz-Sarvise M; Resano L; Berraondo P; Barbés B; Martin-Algarra S; Gúrpide A; Sanmamed MF; de Andrea C; Salazar AM; Melero I
    Ann Oncol; 2018 May; 29(5):1312-1319. PubMed ID: 29554212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
    Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
    J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model.
    Shangguan A; Shang N; Figini M; Pan L; Yang J; Ma Q; Hu S; Eresen A; Sun C; Wang B; Velichko Y; Yaghmai V; Zhang Z
    Cytotherapy; 2020 Jan; 22(1):6-15. PubMed ID: 32005355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
    Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
    Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immunotherapeutic effect of dendritic cells vaccine modified with interleukin-18 gene and tumor cell lysate on mice with pancreatic carcinoma.
    Tang ZH; Qiu WH; Wu GS; Yang XP; Zou SQ; Qiu FZ
    World J Gastroenterol; 2002 Oct; 8(5):908-12. PubMed ID: 12378640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
    Chiang CL; Kandalaft LE; Tanyi J; Hagemann AR; Motz GT; Svoronos N; Montone K; Mantia-Smaldone GM; Smith L; Nisenbaum HL; Levine BL; Kalos M; Czerniecki BJ; Torigian DA; Powell DJ; Mick R; Coukos G
    Clin Cancer Res; 2013 Sep; 19(17):4801-15. PubMed ID: 23838316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
    Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
    Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.
    Takakura K; Koido S; Kan S; Yoshida K; Mori M; Hirano Y; Ito Z; Kobayashi H; Takami S; Matsumoto Y; Kajihara M; Misawa T; Okamoto M; Sugiyama H; Homma S; Ohkusa T; Tajiri H
    Anticancer Res; 2015 Jan; 35(1):555-62. PubMed ID: 25550602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.
    Prins RM; Wang X; Soto H; Young E; Lisiero DN; Fong B; Everson R; Yong WH; Lai A; Li G; Cloughesy TF; Liau LM
    J Immunother; 2013 Feb; 36(2):152-7. PubMed ID: 23377664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study.
    Qiu Y; Yun MM; Xu MB; Wang YZ; Yun S
    Int J Clin Oncol; 2013 Aug; 18(4):657-65. PubMed ID: 22847800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
    Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
    J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
    Alfaro C; Perez-Gracia JL; Suarez N; Rodriguez J; Fernandez de Sanmamed M; Sangro B; Martin-Algarra S; Calvo A; Redrado M; Agliano A; Gonzalez A; Rodriguez I; Bolaños E; Hervás-Stubbs S; Perez-Calvo J; Benito A; Peñuelas I; Vigil C; Richter J; Martinez-Forero I; Melero I
    J Immunol; 2011 Dec; 187(11):6130-42. PubMed ID: 22048768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.
    Hus I; Schmitt M; Tabarkiewicz J; Radej S; Wojas K; Bojarska-Junak A; Schmitt A; Giannopoulos K; Dmoszyńska A; Roliński J
    Leukemia; 2008 May; 22(5):1007-17. PubMed ID: 18323802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.